CRVO - Company ID 0001053691
The table below shows CervoMed Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $322.57K | $1.76M | $1.92M | $1.94M | $3.29M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $5.14M | $6.04M | $5.11M | $4.84M | $5.13M | $3.77M |
CervoMed Inc. reported annual revenue of $4.01M for fiscal year 2025. That is down 58.9% from $9.74M in fiscal 2024. Over the 8 fiscal years shown, annual revenue grew from $40.19K (FY 2010) to $4.01M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $2.98M |
| $2.33M |
| $3.27M |
| $2.38M |
| $2.21M |
| $2.51M |
| Operating income | -$8.11M | -$8.04M | -$6.62M | -$5.30M | -$5.40M | -$3.00M |
| Income tax | - | - | - | - | - | - |
| Net income | -$7.96M | -$7.73M | -$6.26M | -$4.89M | -$4.75M | -$2.32M |
| EPS (diluted) | - | - | - | - | -$0.55 | - |